Product details

By continuing to use our site you consent to the use of cookies as described in our privacy policy unless you have disabled them.
You can change your cookie settings at any time but parts of our site will not function correctly without them.
Authors: Nick Collett (Alliance Manchester Business School (MBS)); S Cartwright (Alliance Manchester Business School (MBS))
Published in: 2000

Abstract

This is the second of a two-case series (300-101-1 and 300-102-1). On 31 March 1995 BASF AG acquired Boots Pharmaceuticals from Boots PLC for DM2bn (£850m) + $70m (£44m). The deal represented the culmination of the strategic goal of BASF, one of the world''s largest chemical companies, and its pharmaceutical subsidiary Knoll AG, to grow by acquisition and organically in the rapidly changing industry. Part One of the case looks at the pharmaceutical industry in 1994, and the strategic alternatives open to Knoll. Part Two looks at integration planning and implementation. A video is available to accompany the case series (300-101-3).
Location:
Industry:
Size:
Multinational
Other setting(s):
1995-1999

About

Abstract

This is the second of a two-case series (300-101-1 and 300-102-1). On 31 March 1995 BASF AG acquired Boots Pharmaceuticals from Boots PLC for DM2bn (£850m) + $70m (£44m). The deal represented the culmination of the strategic goal of BASF, one of the world''s largest chemical companies, and its pharmaceutical subsidiary Knoll AG, to grow by acquisition and organically in the rapidly changing industry. Part One of the case looks at the pharmaceutical industry in 1994, and the strategic alternatives open to Knoll. Part Two looks at integration planning and implementation. A video is available to accompany the case series (300-101-3).

Settings

Location:
Industry:
Size:
Multinational
Other setting(s):
1995-1999

Related